TWA
CPRX

TCI Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

TCI Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-802
Closed -$13.3K – 650
2023
Q1 		$13.3K Buy
802
+201
+33% +$3.32K ﹤0.01% 916
2022
Q4 		$11.2K Hold
601
– – ﹤0.01% 997
2022
Q3 		$8K Hold
601
– – ﹤0.01% 1136
2022
Q2 		$4K Hold
601
– – ﹤0.01% 1601
2022
Q1 		$5K Hold
601
– – ﹤0.01% 1513
2021
Q4 		$4K Buy
+601
New +$3.95K ﹤0.01% 1786

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

TCI Wealth Advisors's CPRX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q2 2023, closing a stake of 802 shares — an estimated $13.3K sold.

TCI Wealth Advisors first reported a position in CPRX in Q4 2021 and held it in 6 quarters. The position peaked at $13.3K in Q1 2023. 248 funds tracked by Wall St. Rank hold CPRX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Catalyst Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 802 Catalyst Pharmaceutical shares in Q2 2023, an estimated $13.3K.
  • TCI Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q4 2021 and held it in 6 quarters.
  • TCI Wealth Advisors's Catalyst Pharmaceutical position peaked at $13.3K in Q1 2023.
  • 248 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.